• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: 22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    6/9/26 9:28:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email
    true --12-31 0001347858 0001347858 2026-06-08 2026-06-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K/A

     

    (Amendment No. 1)

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 8, 2026

     

     

     

    22nd Century Group, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Nevada   001-36338   98-0468420
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    321 Farmington Road, Mocksville, North Carolina

    (Address of Principal Executive Office)

     

    27028

    (Zip Code)

     

    Registrant’s telephone number, including area code: (336) 940-3769

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol   Name of each exchange on which registered
    Common Stock, $0.00001 par value   XXII   NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Explanatory Note

     

    This Amendment No. 1 to the Current Report on Form 8-K (this “Amendment”) amends the Current Report on Form 8-K filed by 22nd Century Group, Inc. (the “Company”) with the Securities and Exchange Commission on June 9, 2026 (the “Original Report”). This Amendment is being filed solely to correct the exercise price of the Inducement Warrants disclosed in Item 1.01 of the Original Report from $0.4626 to $3.57. Except as expressly set forth in this Amendment, all other information set forth in the Original Report remains unchanged and is incorporated herein by reference.

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Warrant Inducement

     

    On June 8, 2026, the Company commenced a warrant inducement offering (the “Warrant Inducement”) with the holders of certain outstanding warrants to purchase up to an aggregate of 5,345,591 shares of common stock (collectively, the “Existing Warrants”), which Existing Warrants are exercisable at an exercise price of $3.57. The Company offered the holders of the Existing Warrants an inducement period whereby the Company agreed to issue new warrants (the “Inducement Warrants”) to purchase up to a number of shares of common stock equal to 100% of the number of shares of common stock issued pursuant to the exercise by the holders of the Existing Warrants, for cash, at a reduced exercise price equal to $0.4626. Each holder agreed to exercise all of their Existing Warrants immediately.

     

    The Inducement Warrants will be issued on substantially the same terms as the Existing Warrants, except that the Inducement Warrants will be exercisable at any time on or after the Company’s stockholders approve the issuance of the Inducement Warrants and the shares of common stock upon the exercise thereof (the “Stockholder Approval Date”), have an expiration date of five years from the Stockholder Approval Date and have an exercise price equal to $3.57. The exercise price of the Inducement Warrants will be subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. In addition, the Inducement Warrants will contain anti-dilution protection provisions relating to a subsequent reverse stock splits and subsequent equity sales of shares of the Company’s common stock or common stock equivalents at an effective price per share lower than the then effective exercise price of such Inducement Warrants and will also adjust in the event of a reverse stock split. The Company also agreed to hold a meeting of stockholders to approve the issuance of the shares of common stock underlying the Inducement Warrants pursuant to applicable Nasdaq rules.

     

    The Inducement Warrants will be issued in reliance upon an exemption from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”). The Company has agreed to, as soon as reasonably practicable, but in any event no later than June 30, 2026, file a registration statement covering the resale of the shares of the Company’s common stock issued or issuable upon the exercise of the Inducement Warrants. The Company shall use commercially reasonable efforts to cause such registration statement to become effective within 45 days (the date such registration statement is declared effective, the “Effectiveness Date”). The shares of common stock issuable under the Existing Warrants were previously registered on Form S-3.

     

    Subject to limited exceptions, a holder of Inducement Warrants will not have the right to exercise any portion of its Inducement Warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by a holder prior to the issuance of any Inducement Warrants, 9.99%) of the shares of common stock then outstanding. At the holder’s option, upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of common stock then outstanding, with any such increase becoming effective upon 61 days’ prior notice to the Company.

     

    The Company agreed that, subject to certain exceptions, until 30 days after the later of the date that all of the shares issuable upon exercise of the Inducement Warrants (the “Warrant Effectiveness Date”), and the date of Stockholder Approval Date, neither the Company nor any of its subsidiaries will issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents.

     

    Each holder participating in the Warrant Inducement shall have the option to elect, in the holder’s sole discretion, to direct that all or a portion of the aggregate proceeds received by the Company from such holder’s exercise of the Existing Warrants hereunder be applied by the Company to redeem shares of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”) held by such holder, at a redemption price equal to the par value of such shares of Series B Preferred Stock (the “Series B Redemption”).

     

     

     

     

    The Company received aggregate gross cash proceeds of approximately $462,800 and redemption of $2,010,000, or 2,010 shares of Series B Preferred Stock from the exercise of the Existing Warrants. The Company has 8,050 shares of Series B Preferred Stock remaining.

     

    Dawson James Securities, Inc. (the “Placement Agent”) acted as the Company’s exclusive placement agent in connection with the Warrant Inducement and the Company has agreed to pay the Placement Agent a cash fee equal to six percent (6.0%) of the aggregate gross proceeds raised in the Warrant Inducement, an additional six percent (6.0%) cash fee of any cash exercise of the Inducement Warrants.

     

    The foregoing summaries of the Inducement Warrants and the inducement letters do not purport to be complete and are subject to, and qualified in their entirety by, such documents attached as Exhibits 4.1 and 10.1, respectively, to this Current Report, which are incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    The disclosure required by this Item, and included in Item 1.01 of this Current Report, is incorporated herein by reference. Neither the Inducement Warrants nor the shares of the Company’s common stock issuable upon exercise of the Inducement Warrants have been registered under the Securities Act, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

     

    Item 3.03. Material Modification to Rights of Security Holders.

     

    On June 10, 2026, the Company will fill a Certificate of Amendment (the “Certificate”) pursuant to Nevada Revised Statutes (“NRS”) Section 78.209 with the Secretary of State of the State of Nevada authorizing a 1-for-20 reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Stock Split”).

     

    Reason for the Reverse Stock Split

     

    The Reverse Stock Split was effected solely to enable the Company to expeditiously restore compliance with the continued listing standard of NASDAQ Capital Market (“NASDAQ”).

     

    Effects of the Reverse Stock Split

     

    Effective Date; Symbol; CUSIP Number. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 12, 2026, and will be reflected with NASDAQ and in the marketplace at the open of business on June 12, 2026 (the “Effective Date”), whereupon the shares of common stock will begin trading on a split-adjusted basis. In connection with the Reverse Stock Split, the Company’s shares of common stock will continue to trade on NASDAQ under the symbol “XXII” but will trade under a new CUSIP Number, 90137F707.

     

    Split Adjustment; No Fractional Shares. On the Effective Date, the total number of shares of the Company’s common stock held by each stockholder will be converted automatically into the number of whole shares of common stock equal to (i) the number of issued and outstanding shares of common stock held by such stockholder immediately prior to the Reverse Stock Split, divided by (ii) 20.

     

    No fractional shares will be issued, and no cash or other consideration will be paid. Instead, the Company will issue one whole share of the post-Reverse Stock Split common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split.

     

    Non-Certificated Shares; Certificated Shares. Stockholders who are holding their shares in electronic form at brokerage firms do not have to take any action as the effect of the Reverse Stock Split will automatically be reflected in their brokerage accounts.

     

    Stockholders holding paper certificates may (but are not required to) send the certificates to the Company’s transfer agent at the address given below. The transfer agent will issue a new share certificate reflecting the terms of the Reverse Stock Split to each requesting stockholder.

     

     

     

     

    Continental Stock Transfer & Trust Company

    ONE STATE STREET, 30th Floor

    New York, New York 10004

    Phone: (917) 262-2378

     

    Please contact Continental Stock Transfer & Trust Company for further information, related costs and procedures before sending any certificates.

     

    State Filing. The Reverse Stock Split was effected by the Company filing the Certificate pursuant to NRS Section 78.209 with the Secretary of State of the State of Nevada on June 10, 2026. The Certificate will not be effective until the Effective Date. A copy of the Certificate is attached hereto as Exhibit 3.1 and incorporated herein by reference.

     

    Stockholder Approval Required. Under Nevada law, because the Reverse Stock Split did not proportionately reduce the authorized shares, Stockholder approval was required in accordance with NRS 78.2055. Under NRS 78.2055, “a corporation that desires to decrease the number of issued and outstanding shares of a class or series held by each stockholder of record at the effective date and time of the change without correspondingly decreasing the number of authorized shares of the same class or series may do so if: (a) The board of directors adopts a resolution setting forth the proposal to decrease the number of issued and outstanding shares of a class or series; and, (b) The proposal is approved by the vote of stockholders holding a majority of the voting power of the affected class or series, or such greater proportion as may be provided in the articles of incorporation, regardless of limitations or restriction on the voting power of the affected class or series.” As described herein, the Reverse Stock Split complies with such requirements.

     

    Capitalization. Prior to the Effective Date of the Certificate, the Company was authorized to issue 500,000,000 shares of common stock. As a result of the Reverse Stock Split, the Company will remain authorized to issue 500,000,000 shares of common. As of June 9, 2026 (immediately prior to the Effective Date), there were 10,326,551 shares of common stock outstanding (including 3,424,094 shares held in abeyance). As a result of the Reverse Stock Split, there will be approximately 516,328 shares of common stock outstanding (including 171,205 shares held in abeyance, and subject to adjustment due to the effect of rounding fractional shares into whole shares). The Reverse Stock Split will not have any effect on the stated par value of the common stock.

     

    Each stockholder’s percentage ownership interest in the Company and proportional voting power remains virtually unchanged as a result of the Reverse Stock Split, except for minor changes and adjustments that will result from rounding fractional shares into whole shares.

     

    All options, warrants and shares of Series B Preferred Stock underlying shares of common stock of the Company outstanding immediately prior to the Reverse Stock Split will be appropriately adjusted as a result of the Reverse Stock Split.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws.

     

    The information required by this Item 5.03 is set forth in Item 3.03 above, which information is incorporated herein by reference.

     

    Item 9.01(d): Financial Statements and Exhibits.

     

    Exhibit 3.1   Certificate of Amendment to Restated Articles of Incorporation
    Exhibit 4.1   Form of Inducement Warrant
    Exhibit 10.1   Form of Inducement Letter
    Exhibit 104   Cover Page Interactive Data File - The cover page XBRL tags are embedded within the inline XBRL document

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      22nd Century Group, Inc.
       
      /s/ Lawrence D. Firestone
    Date: June 9, 2026 Lawrence D. Firestone
      Chief Executive Officer

     

     

     

     

    Get the next $XXII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

    Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    7/21/22 9:12:19 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on 22nd Century Group with a new price target

    Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    6/15/22 7:42:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on 22nd Century Group with a new price target

    Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

    3/8/22 9:21:23 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group (Nasdaq: XXII) Appoints Katherine Rouse-Bailey as Vice President of Marketing

    XXII investing in expanded marketing initiatives to drive VLN® brand awareness and growth MOCKSVILLE, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced the appointment of Katherine Rouse-Bailey as Vice President of Marketing. The enhanced marketing initiatives are designed to strengthen brand awareness, increase consumer trial and support retail sell-through across the Company’s growing commercial footprint. "We are sharpening our focus on marketing and VLN® cigarette brand awareness to drive trial and support repeat purchase," said Larry Firestone

    7/16/26 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes

    Initial 60-Store California Entry Extends XXII's Reduced-Nicotine Rollout Into One of the Nation's Largest and Most Influential Tobacco Markets, With a Pathway to Broader Expansion  MOCKSVILLE, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced the expansion of Pinnacle VLN® into the state of California through an initial approximately 60-store retail trial, establishing the brand's first retail presence in the state and opening another strategically important market for the Company's FDA-authorized reduced-nicotine cigarette platform.  The Californi

    5/21/26 7:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers

    New Product Introduction Broadens XXII's Fast-Scaling Pinnacle Brand Reinforcing Brand Power, Opening New Retail Doors, and Strengthening the Company's Revenue and Margin Expansion Story  MOCKSVILLE, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced the launch of Pinnacle Pure, a new tobacco and water style combustible cigarette, further expanding the Company's growing family of Pinnacle branded products, expected to be sold through multiple top national retailers in the United States and over 2,000 locations.  The expected launch of Pinnacle Pure

    5/18/26 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arno Andrew was granted 17,295 shares, increasing direct ownership by 9,298% to 17,481 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/14/25 4:58:49 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    EVP of Sales and Marketing Manfredonia Robert P was granted 32,429 shares, increasing direct ownership by 5,123% to 33,062 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:40:01 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    VP and Deputy General Counsel Staffeldt Jonathan was granted 37,146 shares, increasing direct ownership by 5,124% to 37,871 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:38:22 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    SEC Filings

    View All

    SEC Form 8-K filed by 22nd Century Group Inc.

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    7/2/26 5:15:31 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by 22nd Century Group Inc.

    424B3 - 22nd Century Group, Inc. (0001347858) (Filer)

    6/26/26 4:15:39 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by 22nd Century Group Inc.

    EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)

    6/25/26 12:15:26 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Group (Nasdaq: XXII) Appoints Katherine Rouse-Bailey as Vice President of Marketing

    XXII investing in expanded marketing initiatives to drive VLN® brand awareness and growth MOCKSVILLE, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced the appointment of Katherine Rouse-Bailey as Vice President of Marketing. The enhanced marketing initiatives are designed to strengthen brand awareness, increase consumer trial and support retail sell-through across the Company’s growing commercial footprint. "We are sharpening our focus on marketing and VLN® cigarette brand awareness to drive trial and support repeat purchase," said Larry Firestone

    7/16/26 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Resignation of John Miller as President of Tobacco

    Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

    5/30/24 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports First Quarter 2026 Financial Results

    Continues VLN® Commercial Expansion with New Stores Selling Proprietary Branded VLN® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the first quarter ended March 31, 2026, and provided an update on recent business highlights. The Company's proprietary reduced nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 2

    5/7/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care